Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin degludec three-times-weekly titration algorithm comparison in insulin-naive type 2 diabetes
2010-022304-50Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of insulin degludec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c after 26 weeks. Started Dec 2010; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-022304-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022304-50.